

January 29-30, 2025 | San Diego, CA
www.spatial-biology-immuno-oncology.com

FREE TO ATTEND
FOR DRUG
DEVELOPERS*
LIMITED PASSES
AVAILABLE



3rd Annual
**Spatial Biology for
Immuno-Oncology Summit**
Harness Spatial Technologies to Power Immunotherapy Research & Clinical Trials

**Interrogating Data Integration
Challenges & Leveraging Multimodal
Tools for Enhanced Tumor Analysis
& Therapeutic Strategies from
Discovery to the Clinic**

Expert Speakers Include:



Oscar Echeagaray
Next Generation
Sequencing
Research Scientist
**Bristol Myers
Squibb**



Alina Ainbinder
Associate Scientific
Director
Takeda



Jack Chen
Scientific Director,
I/O Translational
Research Group
Lead, Precision
Medicine
Abbvie



Lauri Diehl
Executive Director,
Research Pathology
Gilead



Amrita Pati
Senior Director,
Computational Biology,
Clinical Biomarkers &
Diagnostics
Amgen



Daniel Chawla
Senior Biologist,
Computational &
Immuno-Oncology
Pfizer

Proud to Partner With:



Welcome back to the 3rd Spatial Biology for Immuno-Oncology Summit

Building on Spatial Biology's recognition as Nature's Method of the Year in 2020, the surge in investment and technological breakthroughs continue to reshape drug discovery and development. With the rapid integration of AI and ML driving alternative workflows, the field is advancing at unprecedented speed. But how are these innovations transforming practical applications in pharma and biotech infrastructure? And how can spatial biology become more effective and cost-efficient?

The **3rd Spatial Biology for Immuno-Oncology Summit** is the premier industry-led event bringing together pharma, biotech, and solution providers to showcase the **real-world applications of spatial proteomics and transcriptomics in unravelling tissue complexity**.

Explore the latest case studies that integrate computational analysis with spatial biology data to better understand cellular intricacies. We'll discuss standardizing cross-industry methodologies to enhance reproducibility and leveraging spatial biology in clinical settings to transform biomarker discovery, disease stratification, and personalized treatments. Join **100 +** industry experts in **Pathology, Computational Pathology, Bioinformatics, and Translation** to refine a gold-standard methodology for practical applications in immuno-oncology drug development.

What Our Past Attendees Have To Say:

▀▀ There was a tremendous amount of interaction and engagement between the audience and speakers. It had a wonderful think tank atmosphere ▀▀

Leica Biosystems

▀▀ This meeting brought together KOLs from the industry to share best practices and advance the spatial omics field with an eye towards applications in pharmaceutical drug discovery ▀▀

Merck

Your Must-Attend Case Studies:



Utilize spatial technologies to generate comprehensive tissue expression profiles, enabling precise spatial mapping of molecular targets with **Johnson & Johnson**



Distill biological insights from complex spatial omics data using data analytics techniques with **Eli Lilly & Co**



Explore how spatial data informs key decisions on balancing evidence generation with the costs of drug development, identifying when and how much to invest for optimal outcomes with **Amgen**



Assess the strengths and weaknesses of building external and internal spatial biology capabilities to ensure informed resource allocation with **AbbVie & Pfizer**



Leverage AI techniques for identifying complex patterns and relationships within spatial data with **Genentech**

What's New for 2025?

Brand New Companies Joining the Agenda



Brand New Pioneering Speakers:



Carter Allen
Discovery Statistics & Bioinformatics,
Research Scientist
Eli Lilly & Co.



Amrita Pati
Senior Director, Computational Biology,
Clinical Biomarkers & Diagnostics
Amgen



Michael Angelo Rodriguez
Senior Scientist, Discovery
**Johnson & Johnson Innovative
Medicine**




Oscar Echeagaray
Next Generation Sequencing Research
Scientist
Bristol Myers Squibb

Breaking New Ground: The Growth of Spatial Biology

SPATIAL GENOMICS MARKET

3.23 billion



Oncology is set to be the primary growth factor for spatial biology, particularly as the global cancer burden continues to rise. As precision medicine becomes the standard of care, spatial biology technologies will play a crucial role in unraveling tumor heterogeneity and guiding personalized treatment strategies. By integrating multi-omics data and identifying predictive biomarkers, spatial biology will enhance our ability to improve patient outcomes, solidifying its place at the forefront of oncology research and treatment.

Key Sessions Not To Miss:



Integrating Spatial Data with Clinical Outcomes

Learn how recent studies are linking spatially resolved data to clinical outcomes, paving the way for novel biomarkers and personalized treatment strategies




Artificial Intelligence in Spatial Biology

Delve into how AI is revolutionizing spatial data analysis, enabling more accurate modeling of 3D tumor structure



Immunotherapy & Spatial Mapping

Discover the role of spatial biology in enhancing the efficacy of immunotherapies, including the identification of predictive toxicology effects



Your Expert Speakers

3rd Annual
Spatial Biology for
Immuno-Oncology Summit

January 29-30, 2025 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Alina Ainbinder
Associate Scientific
Director
Takeda



Anjali Rao
Research Scientist,
Bioinformatics
Gilead



Amrita Pati
Senior Director,
Computational Biology,
Clinical Biomarkers &
Diagnostics
Amgen



Bhavana Palakurthi
Scientist
Kite Pharma



**Carmen Ballesteros-
Merino**
Senior Principal Scientist
Bristol Myers Squibb



Chen Hao Lo
Postdoctoral Research
Fellow
Amgen



Daniel Chawla
Senior Biologist,
Computational &
Immuno-Oncology
Pfizer



Gulpreet Kaur
Vice President of
Commercial Development
Elucidate Bio



Jack Chen
Scientific Director, I/O
Translational Research
Group Lead, Precision
Medicine
Abbvie



Joao Costa
Scientific Associate
Director
Takeda



J. Spencer Schwarz
Applications Manager
Bruker Spatial Biology



Lauri Diehl
Executive Director,
Research Pathology
Gilead



Mathieu Marella
Principal Scientist
**Johnson & Johnson
Innovative Medicine**



**Michael Angelo
Rodriguez**
Senior Scientist, Discovery
**Johnson & Johnson
Innovative Medicine**



Oscar Echeagaray
Next Generation
Sequencing Research
Scientist
Bristol Myers Squibb



Paul Tumeh
Chief Executive Officer
BioGraph 55



Sandra Garcia
Senior Scientist
**Johnson & Johnson
Innovative Medicine**



Sergey Novitskiy
Senior Scientist
Amgen



Sripad Ram
Digital Pathology & Image
Analysis Group Lead
Pfizer



Suzanne Coberly
Senior Director,
Translational Pathology
Bristol Myers Squibb

Conference Day One

Wednesday, January 29, 2025



8.00 Registration & Networking



Sergey Novitskiy
Senior Scientist
Amgen

8.55 Chair's Opening Remarks

Transforming Drug Development: Innovations in Omics Integration & Spatial Technology



Amrita Pati
Senior Director,
Computational Biology,
Clinical Biomarkers &
Diagnostics
Amgen

9.00 Inference of Drug Response & Resistance Mechanisms using Multi-modal Omics Analysis

- Balancing evidence generation with cost of drug development: when and how much?
- Navigating data integration and analysis paradigms used in therapeutic development
- Improving the development of models for hypothesis generation

9.30 **Panel Discussion: Innovations in Spatial Technology Integration: Pioneering Solutions for Complex Biological Questions**

- Exploring new software, technologies, and methodologies for integrating complex spatial data with various omics layers
- Sharing examples of successful application and integration of new tools in research settings
- Delving into emerging trends and future developments in spatial technology integration and their potential impact on the field



Amrita Pati
Senior Director, Computational Biology,
Clinical Biomarkers & Diagnostics
Amgen



Sripad Ram
Digital Pathology & Image
Analysis Group Lead
Pfizer



Suzanne Coberly
Senior Director,
Translational Pathology
Bristol Myers Squibb

10.15 **Breakout Roundtable Discussions**

This session is your opportunity to share your most pressing challenges and work as a group to come up with solutions that you can implement right away. Each topic area will have several small groups, and each group will have 20 minutes to discuss their thoughts on the given topic. Groups will then share their findings with all attendees during the final 10 minutes, giving you maximum exposure to new ideas

Comparison of Currently Available Spatial Technologies: Proteomics for Immuno-Oncology

Compare spatial transcriptomics technologies in immuno-oncology, from low-plex to high-plex, highlighting their ability to profile tumor-immune interactions, identify critical gene expression patterns, and assess cost-efficiency trade-offs for biomarker discovery and treatment personalization, while considering timelines and data analysis challenges.

Comparison of Currently Available Spatial Technologies: Transcriptomics for Immuno-Oncology

Compare spatial proteomics technologies in immuno-oncology, from low-plex to high-plex, focusing on their role in profiling the tumor-immune interface, identifying key protein expression patterns, and evaluating cost-efficiency trade-offs for biomarker discovery and therapeutic targeting, while addressing timelines and sample preparation challenges.



10.45 Speed Networking

As the Spatial Biology community is reunited, this valuable session will ensure you get the chance to reconnect with peers and make brand new connections! This structured networking opportunity will pair you with fellow attendees for several 3-minute introductions, ensuring you have the opportunity to meet and network with your industry colleagues



11.15 Morning Break & Networking

Conference Day One

Wednesday January 29, 2025

From Data to Discovery: Navigating High Dimensionality & Effective Communication in Spatial Biology

11.45 How Spatial-Based Information Can Guide Therapeutic Strategy From Discovery to the Clinic



Paul Tume
Chief Executive Officer
BioGraph 55

- The solid tumor microenvironment is an ecosystem comprised of distinct niches (or “zip codes”) – cell-types and their interactions within specific niches are highly conserved
- Spatial-based biological information is unique, non-overlapping with methods that isolate single-cells or homogenize tumor samples, and clinically relevant
- This short talk will focus on how BioGraph 55 used spatial-based information to develop their therapeutic strategy from target discovery to drug candidate

12.15 Iterative Spatial Omics: A holistic Framework for Interrogating the TME with High-Plex Spatial Multi-Omics



Gulpreet Kaur
Vice President
of Commercial
Development
Elucidate Bio

- Integrating Spatial Proteomics, Genomics & Transcriptomics: This talk introduces a scientific framework leveraging iterative spatial multi-omics to resolve the complexity of the tumor microenvironment (TME), enabling the discovery of predictive biomarkers and mechanisms driving therapeutic response or resistance
- Insights from EBV+ vs. EBV- TME in B-cell malignancies: Using spatial proteomics, key differences in cell types, functionality, and cellular neighborhood changes between EBV-positive and EBV-negative TMEs are identified. Proximity-linked exhaustion scores are used to stratify cHL tumors, while spatial transcriptomics provides mechanistic insights for patient stratification
- What can Elucidate Bio do for you? Single-slide spatial multi-omic data generation & analysis tailored to advance biomarker discovery and therapeutic development



12.35 Lunch & Networking

Harnessing Spatial Omics to Uncover Disease Mechanisms & Drive Biomarker Discovery in Immuno-Oncology & Beyond

1.35 Leveraging Multimodal Profiling of FFPE Tissue to Characterize Disease Biology & Enable Novel Early Target Identification in Crohn's Disease



Anjali Rao
Research Scientist,
Bioinformatics
Gilead

- Demonstrating how spatial transcriptomics combined with single nuclei RNAseq and multiplex immunofluorescence from FFPE tissue provides a comprehensive view of disease biology, with parallels to immuno-oncology applications
- Showcasing how innovative bioinformatics approaches and histologically guided features can be applied to analyze curated patient cohorts and drive target discovery
- Presenting a novel framework that, while developed for inflammatory diseases, can be adapted to uncover actionable targets in tumor immunology and improve immunotherapy strategies

2.05 Spatially Profiling Human Synovial Tissue in Inflammatory Arthritis



Michael Angelo Rodriguez
Senior Scientist,
Discovery
Johnson & Johnson
Innovative Medicine


- Leveraging single-cell transcriptomics data in inflammatory arthritis
- Best practices for characterizing architecture and cell distribution in human synovial joint
- Understanding impact of disease activity on tissue expression



2.35 Afternoon Break & Networking

Conference Day One

Wednesday, January 29, 2025



January 29-30, 2025 | San Diego, CA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



J. Spencer Schwarz
Applications Manager
**Bruker Spatial
Biology**

3.05 **EpicIF & Cellscope Deliver the Promise of Approachable, Scalable, Spatial Proteomics**

- Spatial Proteomics, recognized as Nature Methods 'Method of the year 2024', earns this honorific by delivering insights about the spatial organization of biology's functional unit of health and disease: proteins. Proteins are not limited to coding regions but include post-translational modifications and interactomes, underscoring the real complexity of etiology. This added complexity explains the power of proteomics to discover new methods of diagnosis and treatment. Cellscope is uniquely positioned to assist in the exploration of this post-transcriptional world
- Cyclic multiplexing of immunofluorescent probes (cyclic mIF) provides the most direct, most easily interpreted, and most clinically relevant proteomic data. Here Cellscope with EpicIF represents a breakthrough in the field, delivering on the promise of fast, accessible, and scalable cyclic mIF data through orders-of-magnitude expansion in both the number of targeted probes compatible with the method, and the speed with the method can be conducted
- - Cyclic mIF is fundamentally an imaging technology, where the acuity of captured images directly correlates to the acuity of insights. Cellscope delivers exceptional proteomic data, with spatial sampling at up to 182 nm/pixel and a 300% increase in SNR over background through HDR imaging; all at scale, and all while respecting compatibility with a clinical pathology workflow



Joao Costa
Scientific Associate
Director
Takeda

3.20 **Decoding Tumor Microenvironments: Using Spatial Omics for Discovering New Biomarkers**

- Highlighting techniques for identifying and validating new biomarkers using spatial omics
- Advancing methodologies for validating novel biomarkers discovered through spatial omics, including experimental validation, cross-validation with other techniques, and integration with clinical data.
- Examining how these biomarkers have been translated into clinical insights or applications, such as improving diagnostics, guiding therapeutic decisions, or predicting patient outcomes



Bhavana Palakurthi
Scientist
Kite Pharma

3.50 **Challenges & Opportunities in Spatial Omics for Clinical Biomarker Development**

- Highlighting the significance of the TME in disease progression and treatment
- Discussing how findings from spatial omics could influence clinical practice, such as personalised medicine approaches
- Overcoming challenges in translating spatial omics discoveries into routine clinical biomarkers



Sergey Novitskiy
Senior Scientist
Amgen

4.20 **Chair's Closing Remarks**



4.30 **Spatial Biology for Immuno-Oncology Drinks' Reception**

Join our dedicated drinks reception to further connect and network with like-minded experts!

5.30 **End of Day One**

Conference Day Two

Thursday, January 30, 2025



8.00 Coffee & Networking



Daniel Chawla
Senior Biologist,
Computational &
Immuno-Oncology
Pfizer

8.55 Chair's Opening Remarks

Navigating the Landscape: Building Spatial Biology Capabilities & Advancing Drug Discovery

9.00 **Panel Discussion: Navigating Strategic Choices: Building Internal Capabilities vs. Partnering with External Experts in Spatial Biology**

- Outlining the factors that influence whether an organization should build internal spatial biology capabilities or work with external partners
- Delving into case studies of organizations that chose to scale through internal development and those that successfully worked with CROs to expand their capabilities
- Analysing how hybrid models provide flexibility, reduce risks, and ensure a balance of internal control and external expertise



Jack Chen
Scientific Director,
I/O Translational
Research Group
Lead, Precision
Medicine
Abbvie



Alina Ainbinder
Associate Director
Takeda



**Carmen Ballesteros-
Merino**
Senior Principal
Scientist
Bristol Myers
Squibb



Mathieu Marella
Principal Scientist
Johnson & Johnson
Innovative Medicine



Oscar Echeagaray
Next Generation
Sequencing Research
Scientist
Bristol Myers Squibb

9.45 **From Bench to Breakthroughs: Leveraging Spatial Transcriptomics Platforms in Early Discovery & Beyond**

- Discussing how spatial transcriptomics can be utilized in early drug discovery to identify novel targets and understand disease mechanisms at a cellular level
- Exploring the benefits of integrating spatial transcriptomics with other orthogonal technologies
- Addressing the current challenges in spatial transcriptomics, such as data complexity, cost, and technical limitations, and discussing potential solutions and future directions



10.15 Morning Break & Networking

Enhancing Target Profiling & Understanding Immune Dynamics to Navigate Cell-Cell Interactions

11.00 **Innovation in Preclinical & Translational Safety: Unveiling Spatial Target Expression Profiling with CosMx**



Sandra Garcia
Senior Scientist
Johnson & Johnson
Innovative Medicine

- Leveraging cutting-edge CosMx technology to generate comprehensive tissue expression profiles in human tissues, enabling precise spatial mapping of molecular targets within complex tissues
- Achieving unparalleled spatial resolution by using CosMx to profile target expression at the single-cell level within tissue microarrays, unlocking insights into cell-specific responses and behaviors in several tissues in one slide
- Utilizing spatial transcriptomics data to assess safety profiles and identify potential toxicological effects, driving informed decision-making in drug development and preclinical safety assessments



11.30 **Roundtable: Effective Communication of Data Analyses in Spatial Omics**

- What are the most effective ways to distill the complexity of high-throughput spatial omics data for clear communication?
- Which data visualization and analysis techniques have you found most impactful in driving insights
- How do you tailor the presentation of spatial omics findings for audiences with varying levels of technical expertise?

Conference Day Two

Thursday, January 30, 2025



12.00 Lunch & Networking



Chen Hao Lo
Postdoctoral Research
Fellow
Amgen

1.00 Spatial Transcriptomics Reveal Interplay Between CAFs & Tumor-phagocytic TAMs that Governs Immunosuppression

- Exploring the technical aspects and innovations that enable high-resolution mapping of cellular interactions
- Detailing how high-resolution spatial mapping reveals insights into cell-cell interactions within tissues.
- Reviewing examples where these techniques have been used to study immune cell interactions, tumor-stroma dynamics, and neuronal networks

Unifying Spatial Technologies & Standardizing Data Processing

1.30 Panel Discussion: Standardizing Data Processing Across Spatial Biology Platforms

- Summarising the challenges of inconsistencies in data processing due to varied computational tools and resources
- Outlining current efforts and proposals for developing universal or standardized methods
- Navigating case studies of successful standardization initiatives and their impact
- Discussing current progress in analyzing spatial data, including advancements in computational tools and algorithms



Sripad Ram
Digital Pathology & Image Analysis Group Lead
Pfizer



Lauri Diehl
Executive Director, Research Pathology
Gilead



Daniel Chawla
Senior Biologist,
Computational &
Immuno-Oncology
Pfizer

2.00 Closing Remarks

2.05 End of Conference

“The content and agenda were very solid. I enjoyed interacting with peers and sharing our work”

AbbVie

“Excellent collection of speakers, great opportunities for networking”

Arcus Biosciences

Your Dedicated Global Platform to Foster New & Existing Relationships within the Rapidly Expanding Spatial Biology Field

The **3rd Spatial Biology for Immuno-Oncology Summit** returns to unite over **100+** industry stakeholders and decision makers, providing a dynamic platform for sharing the latest innovations and addressing challenges in harnessing spatial biology tools specifically for immuno-oncology drug development.

As our spatial biology community rapidly expands, there is an increasing demand for the right partners and solutions to fully leverage these groundbreaking technologies. This summit is an unmissable opportunity to exhibit, showcase, and elevate your brand among an elite audience of experts dedicated to enhancing their spatial biology capabilities, including industry leaders from **Pfizer, Amgen, Takeda**, and others.

Our thought leaders from pharma and biotech are actively seeking long-term partners to support them in:



Analyzing Complex Tumor Microenvironments

Collaborate to implement advanced imaging platforms that enable in-depth analysis of disease complexity and intricate tissue patterns within tumor samples, uncovering critical insights for therapeutic development.



Adopting Innovative Spatial Technologies

Present your state-of-the-art spatial biology solutions to empower pharma and biotech companies in enhancing their understanding of tumor biology and immune interactions



Streamlining Multi-Omics Data Integration

Work together to seamlessly integrate datasets from various omics platforms, creating a comprehensive analytical framework that accelerates discoveries and enhances clinical decision-making.




Enhancing Efficiency with AI Solutions


Leverage AI-powered pathology for accurate analyses of tissue patterns, significantly reducing time and resource expenditures while maximizing research outcomes.

By aligning with the leading voices in the field, you'll not only elevate your brand's visibility but also play a vital role in shaping the future of immuno-oncology drug development.

SENIORITY OF ATTENDEES*



AUDIENCE BREAKDOWN*



Based on data from the 2024 event

GET INVOLVED



Jack Hayes
Sales Relationship Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Bruker Spatial Biology – Spotlight Partner

Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial solutions, including instruments, assays, software, and services to support life sciences research. The CosMx™ Spatial Molecular Imager enables high-plex spatial transcriptomics at single-cell resolution, with data analysis supported by the cloud-based AtoMx™ Spatial Informatics Platform. Designed for whole-tissue exploration, the GeoMx® Digital Spatial Profiler provides high-plex multiomic readouts while the CellScape™ Precise Spatial Proteomics platform enables high dynamic range biomarker analysis. The nCounter® Analysis System facilitates rapid, sensitive profiling of gene and miRNA expression. Access to these cutting-edge technologies is provided by Canopy Multiomic Services.

www.brukerspatialbiology.com



Elucidate Bio - Innovation Partner

Elucidate Bio provides multi-modal spatial biology services, enabling same-tissue imaging of DNA, RNA, and protein with single-cell spatial resolution. Powered by technology licensed from Sizun Jiang at Harvard Medical School/BIDMC, we specialize in single-slide spatial proteomic, transcriptomic, and genomic data generation and analysis. With rigorous quality control, we deliver high-quality data, detailed analysis, and actionable insights to advance biomarker discovery, therapeutic development, and precision medicine. Contact Elucidate Bio to explore innovative spatial pipelines tailored to your program needs.

www.elucidatebio.com/

“The agenda was very well thought out and the networking event was very well attended”

Oncology & Primary Healthcare Center Solutions &
Group Marketing Manger, Roche

GET INVOLVED



Jack Hayes

Sales Relationship Manager

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.spatial-biology-immuno-oncology.com/take-part/register



Tel: +1 617 455 4188



Email: info@hansonwade.com



Unlock New Insights into Tumor Biology: Delve into the latest research and innovations in spatial biology that are redefining our understanding of tumor microenvironments and immune interactions. Discover how these advancements can inform your research and clinical strategies.



Enhance Your Research Capabilities: Learn about cutting-edge spatial technologies and methodologies that can elevate your research efforts. Gain practical knowledge on how to effectively implement these tools to advance your studies in immuno-oncology.



Collaborate with Leading Experts: Engage with industry experts in an interactive environment. Build valuable relationships that can lead to collaborative projects, shared insights, and enhanced opportunities in the field of immuno-oncology.

Drug Developer*

Conference Only

Free Attendance - [Click Here to Register](#)

Solution Provider**

Register Online & Save \$100!

On the Door Price

Conference Only

\$3,599

\$3,699

*A "drug developer" must have a pipeline candidate and must not provide solutions or services for a fee to any other company. As a strategic investment focused meeting, the goal is to foster investment opportunities in spatial technology, between drug developers and technology providers. Therefore, all bookings under the drug developer category are subject to the organizer's approval. T&Cs apply

** Solution providers refer to representatives from a CRO, software, or preclinical service provider organization that partners and provides services to drug developer/contract research organizations.

Team Discounts

- 10% discount – 3 Attendees
- 15% discount – 4 Attendees
- 20% discount – 5 + Attendees

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

DoubleTree by Hilton Hotel San Diego - Mission Valley
7450 Hazard Center Dr, San Diego, CA 92108, United States

<https://www.spatial-biology-immuno-oncology.com/take-part/register>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



12

+1 617 455 4188 @ info@hansonwade.com

www.spatial-biology-immuno-oncology.com

